Clearmind Medicine IncNASDAQ:CMND
- LAST PRICE1.1600
- TODAY'S CHANGE (%)-0.0400 (-3.3333%)
- Bid / Lots1.1600/ 2
- Ask / Lots1.2100/ 29
- Open / Previous Close1.1620 / 1.2000
- Day Range
- 52 Week Range
- Volume22,994
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CMND |
|---|---|---|
| 09:36 ET | 500 | 1.162 |
| 09:50 ET | 1594 | 1.15 |
| 10:03 ET | 250 | 1.175 |
| 10:10 ET | 100 | 1.1962 |
| 10:32 ET | 169 | 1.19 |
| 10:33 ET | 333 | 1.16 |
| 10:37 ET | 100 | 1.175 |
| 10:50 ET | 617 | 1.175 |
| 11:24 ET | 150 | 1.1732 |
| 11:27 ET | 100 | 1.1509 |
| 11:31 ET | 100 | 1.1508 |
| 11:33 ET | 10200 | 1.1999 |
| 11:36 ET | 100 | 1.16 |
| 11:42 ET | 283 | 1.175 |
| 11:54 ET | 200 | 1.19 |
| 12:16 ET | 992 | 1.17 |
| 12:30 ET | 270 | 1.19 |
| 12:32 ET | 300 | 1.18 |
| 01:12 ET | 2388 | 1.17 |
| 01:50 ET | 100 | 1.196 |
| 02:13 ET | 510 | 1.1604 |
| 02:26 ET | 250 | 1.18 |
| 02:29 ET | 1400 | 1.18 |
| 03:59 ET | 100 | 1.16 |
Apr 17, 2024
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders, from 7:49AM ET on Wednesday Apr 17, 2024 by Dow Jones
7:49AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 10, 2024
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders, from 7:17AM ET on Wednesday Apr 10, 2024 by Dow Jones
7:17AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 9, 2024
Clearmind Medicine CEO Issues Letter to Shareholders, from 8:07AM ET on Tuesday Apr 09, 2024 by Dow Jones
8:07AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Clearmind Medicine Inc | 3.7M | 0.0x | --- |
Biophytis SA | 3.5M | -0.1x | --- |
Virpax Pharmaceuticals Inc | 3.6M | -0.2x | --- |
Revelation Biosciences Inc | 3.6M | 0.1x | --- |
Psycheceutical Bioscience Inc | 3.5M | -0.1x | --- |
Biostax Corp | 4.0M | -2.4x | --- |
Company Information
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 15 patent families, including 27 granted patents and 24 pending applications. The portfolio spans a range of jurisdictions, including the United States, Europe, India, and China.
Contact Information
- Headquarters
- 101-1220 West 6Th AvenueVANCOUVER, BC, Canada V6H 1A5
- Phone
- 604-260-1566
- Fax
- 604-689-2646
Executives
- Independent Chairman of the Board
- Amitay Weiss
- Chief Executive Officer
- Adi Zuloff-Shani
- Chief Financial Officer
- Alan Rootenberg
- Vice President - Business Development
- Mark Haden
- Director
- Asaf Itzhaik
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 3.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-30.92 |
Book Value | $1.62 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
